$104 Million is the total value of RP Management, LLC's 3 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIOHAVEN LTD | $76,378,547 | +8.7% | 2,936,507 | 0.0% | 73.72% | +2.1% | ||
| BCRX | BIOCRYST PHARMACEUTICALS INC | $27,230,770 | +0.6% | 3,846,154 | 0.0% | 26.28% | -5.5% | |
| VIRX | VIRACTA THERAPEUTICS INC | $3,848 | -26.2% | 3,700 | 0.0% | 0.00% | -20.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOHAVEN PHARMACTL HLDG CO L | 16 | Q3 2022 | 77.6% |
| EPIZYME INC | 11 | Q2 2022 | 44.1% |
| EPIZYME INC | 11 | Q2 2022 | 13.9% |
| VIRACTA THERAPEUTICS INC | 11 | Q3 2023 | 5.7% |
| CYTOKINETICS INC | 10 | Q1 2021 | 7.6% |
| SUNESIS PHARMACEUTICALS INC | 9 | Q4 2020 | 0.1% |
| IMMUNOMEDICS INC | 8 | Q3 2020 | 55.7% |
| BIOCRYST PHARMACEUTICALS INC | 8 | Q3 2023 | 52.0% |
| BIOHAVEN LTD | 4 | Q3 2023 | 73.7% |
View RP Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CYPRESS BIOSCIENCE INC | December 23, 2010 | 3,815,000 | 9.9% |
View RP Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 4 | 2022-08-16 |
| 13F-HR | 2022-08-10 |
| 4 | 2022-05-19 |
| 13F-HR | 2022-05-11 |
View RP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.